secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vivani Medical, Inc. (VANI)
CIK:        0001266806
Form:       8-K
Filed at:   2025-09-04T23:59:59+00:00
Accession:  0001753926-25-001431
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vivani Medical plans Phase 1/2 trials for NPM-139 semaglutide implant; H1 2026 start
--------------------------------------------------------------------------------

- NPM-139 is a semaglutide implant for chronic weight management in obese/overweight patients.
- Phase 1 study expected to start H1 2026 pending regulatory clearance; designed for safety, tolerability, PK.
- Phase 2 dose-ranging study planned to follow Phase 1, pending enabling results and regulatory feedback.
- NPM-139 aims to deliver Wegovy-level efficacy with once or twice-yearly administration.
- Positive preclinical data and promising LIBERATE-1 results for NPM-115 (exenatide) support program.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1266806/000175392625001431/0001753926-25-001431-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1266806/000175392625001431/vani-20250904.htm
  HTML page:      https://secwatch.observer/filing/0001753926-25-001431

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer